Specialty Pharmacy Times spoke to Milayna Subar, MD, vice president and national practice leader in oncology for the Oncology Therapeutic Resource Center (TRC) at Express Scripts, to learn more about how access to clinical practice guidelines in oncology can help shape the complex landscape of cancer treatment.
The FDA today approved OraQuick In-Home HIV Test, the first over-the-counter HIV test that gives users results without having to send samples off to a lab.
Adult patients with refractory chronic gout (RCG) treated bi-weekly with Krystexxa (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain, and physical function, according to an analysis in The Journal of Rheumatology.
To get perspective on the ACA ruling's impact on specialty pharmacy, Specialty Pharmacy Times interviewed D'vorah Graeser, PhD, about the Biologics Price Competition and Innovation Act (BPCIA).
The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc announced a significant expansion of their partnership to support clinical development of Celator's CPX-351 (cytarabine:daunorubicin) liposome injection for treatment of adults with acute myeloid leukemia (AML).
MHA's BizMed Program was created to offer MHA members a comprehensive portfolio of medical products, services and innovative business solutions to help them achieve operational efficiency while controlling bottom line performance.
Chiasma recently presented data at the annual meeting of The Endocrine Society that show Octreolin (oral octreotide) reduced pituitary growth hormone secretion in healthy volunteers as effectively as shown in published studies of injectable octreotide.
Pharmacies and retail clinics are offering HIV testing in an effort to help reach the CDC's goal of testing every adolescent and adult in the country.
June 27th is National HIV Testing Day, an annual campaign coordinated by the National Association of People with AIDS to encourage people of all ages to "Take the Test, Take Control."
The Midwest Business Group on Health in collaboration with Pharmacy Outcomes Specialists announced the keynote speakers and agenda for the sixth annual Pharmacy Benefits Academy (PBA) to be held July 31-August 1 at the Westin O'Hare.
A recent FDA study determined that current nucleic acid testing (NAT) of the plasma of donated blood is adequate for the detection of the hepatitis C virus (HCV).
Community Specialty Pharmacy Network (CSPN) has partnered with CoverMyMeds to automate the prior authorization process.
Sanofi's Genzyme unit announced in a press release earlier last week that the company has submitted an application to regulatory authorities for approval of Lemtrada (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS).
BioMed Intelligence, Inc (BMI), a leader in providing technology products and services for the healthcare community, recently announced its award by Kerr Health to integrate Kerr Health's Specialty Pharmacy and Long Term Care (LTC) data into BMI's Data Warehouse Solution.
Diplomat Specialty Pharmacy CEO Phil Hagerman was recently invited to participate in a forum on fostering greater opportunity, innovation, and job creation in today's economy.
On June 20th, 2012, the longest day of the year, the Alzheimer's Association is asking participants to run, walk, bike, or engage in some kind of endurance activity for 16 consecutive hours to honor those facing Alzheimer's disease.
The FDA recently tested samples of compounded hydroxyprogesterone caproate (the active ingredient in Makena) to measure their potency and purity.
SXC Health Solutions Corp announced that it has been awarded Specialty Pharmacy Accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.
Phase 3 study findings showed that patients with active moderate to severe rheumatoid arthritis (RA) who received an investigational intravenous (IV) formulation of the anti-tumor necrosis factor (TNF)-alpha therapy Simponi (golimumab) demonstrated significant improvements in signs, symptoms, and disease activity.
The FDA will take an additional 3 months to review the drug application for Truvada as a preventive HIV treatment to account for updated safety materials submitted by Gilead.
Argus Health Systems, Inc, a leading transparent pharmacy benefits administrator, recently announced that it has established a Preferred Specialty Program with Amber Pharmacy to provide expanded network options.
The FDA approved Genentech, Inc's pertuzumab injection (Perjeta) for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Diplomat Specialty Pharmacy, the nation's largest, privately owned specialty pharmacy, announced that pharmacy executive, Gary W. Kadlec, has joined the company and will be serving as president.
Pharmaceutical Strategies Group, LLC, recently announced the immediate availability of a suite of specialty pharmacy management services featuring their RxDiagnostic for Specialty service.
New efficacy and safety data from the Phase 3 PHOENIX 1 study, 1 of 2 pivotal registration trials, showed that maintenance treatment with Stelara (ustekinumab) for up to 5 years resulted in consistent, significant clinical response in adults with moderate to severe plaque psoriasis.
MedPro Rx receives accreditation from the Accreditation Commission for Health Care, Inc, in the areas of Infusion Pharmacy Services, Infusion Nursing Services, and Specialty Pharmacy Services.
Bristol-Myers Squibb's investigational drug facilitates improved immune response in lung cancer, kidney cancer, and melanoma patients, according to a study presented at the American Society of Clinical Oncology (ASCO).
Beckie Fenrick, PharmD, MBA, discusses emerging trends in specialty pharmacy including companion diagnostics and personalized care.
Girls who received mantle radiation for childhood cancer were found to be at elevated risk for secondary breast cancer later in life.
Afatinib shows promise as a treatment for patients with advanced lung adenocarcinomas who tested positive for EGFR mutations.
